Ionis Pharmaceuticals(US:IONS) Seeking Alpha·2026-02-27 07:54Core Insights - Ionis Pharmaceuticals, Inc. (IONS) has experienced a significant rally in its stock price following the positive data release for its drug Tryngolza (olezarsen), which treats severe hypertriglyceridemia, indicating it may become the new standard of care [2] Group 1: Company Performance - The strong data from Tryngolza suggests a promising future for Ionis Pharmaceuticals, potentially positioning the company as a leader in the treatment of familial chylomicronemia syndrome [2] - The market analyst Bret Jensen, with over 13 years of experience, highlights the potential for high returns in the biotech sector, particularly through investments in companies like Ionis [2] Group 2: Investment Opportunities - The Biotech Forum, led by Bret Jensen, offers a model portfolio featuring 12-20 high upside biotech stocks, including Ionis, and provides live discussions on trade ideas and weekly market commentary [2]